simendan has been researched along with milrinone in 76 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (6.58) | 18.2507 |
| 2000's | 23 (30.26) | 29.6817 |
| 2010's | 36 (47.37) | 24.3611 |
| 2020's | 12 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Acar, D; Klaus, W; Rump, AF | 1 |
| Hettrick, DA; Pagel, PS; Warltier, DC | 1 |
| Haikala, H; Kaheinen, P; Levijoki, J; Lindén, IB | 1 |
| Castell, M; Hasenfuss, G; Just, H; Kretschmann, B; Maier, LS; Pieske, B | 1 |
| Bowman, P; Haikala, H; Paul, RJ | 1 |
| Haikala, H; Kaheinen, P; Levijoki, J; Pollesello, P | 2 |
| Young, JB | 1 |
| Gattis, WA; Gheorghiade, M; Jain, P; Klein, L; Massie, BM | 1 |
| Battagliese, A; Bucciarelli Ducci, C; Celotto, A; De Luca, L; Fedele, F; Palombaro, GL; Proietti, P | 1 |
| Bornstein, SR; Fournell, A; Picker, O; Scheeren, TW; Schwarte, LA | 1 |
| Coopersmith, CM | 1 |
| Harjola, VP; Siirilä-Waris, K; Suojaranta-Ylinen, R | 1 |
| Mehra, MR | 1 |
| Al-Shawaf, E; Ayed, A; Dehrab, N; Radomir, B; Tarazi, R; Vislocky, I | 1 |
| Papp, JG; Pollesello, P; Varró, AF; Végh, AS | 1 |
| Wessel, DL | 1 |
| Brizard, CP; Horton, SB; Mynard, JP; Nørgaard, MA; Penny, DJ; Shekerdemian, LS; Stocker, CF | 1 |
| Pagel, PS | 1 |
| Cromheecke, S; De Hert, SG; Lorsomradee, S; Van der Linden, PJ | 1 |
| Barraud, D; Damy, T; Faivre, V; Gayat, E; Heymes, C; Mebazaa, A; Payen, D; Shah, AM; Welschbillig, S | 1 |
| Farmakis, D; Nieminen, M; Parissis, JT | 1 |
| Kajimoto, K; Kawana, M; Watanabe, H | 1 |
| Banfor, PN; Campbell, TJ; Cox, BF; Fryer, RM; Marsh, KC; Polakowski, JS; Preusser, LC; Reinhart, GA | 1 |
| Fryer, RM; Marsh, KC; Polakowski, JS; Segreti, JA | 1 |
| Cromheecke, S; De Hert, SG; Lorsomradee, S; Van der Linden, PJ; vanden Eede, H | 1 |
| Baumert, JH; Hein, M; Roehl, AB; Rossaint, R; Scherer, K; Steendijk, P | 1 |
| Ackermann, D; Grottke, O; Hein, M; Rieg, AD; Rossaint, R; Schälte, G; Schroth, SC | 1 |
| Alexander, PM; Butt, WW; Penny, DJ; Ryerson, LM; Shann, FA; Shekerdemian, LS | 1 |
| Anslot, C; Clement de Clety, S; Detaille, T; Joomye, R; Matta, A; Momeni, M; Poncelet, AJ; Rennotte, MT; Rubay, J; Veyckemans, F | 1 |
| Hoffman, TM | 1 |
| Hjortdal, VE; Hyldebrandt, JA; Larsen, SH; Ravn, HB; Schmidt, MR | 1 |
| Läer, S; Vogt, W | 1 |
| Kilo, J; Schermer, E; Schweigmann, U; Velik-Salchner, C | 1 |
| Jovicić, B; Kosutić, J; Nikolić, L; Prijić, S; Rakić, S; Stajević, M; Vukomanović, V | 1 |
| Gongadze, NV; Sukoyan, GV | 1 |
| Cho, S; Hara, T; Higashijima, U; Maekawa, T; Matsumoto, S; Sumikawa, K; Tosaka, S | 1 |
| Fournell, A; Picker, O; Scheeren, TW; Schwarte, LA | 1 |
| Bigam, DL; Cheung, PY; Churchill, T; Joynt, C; Manouchehri, N; Vento, M | 1 |
| Noori, S; Seri, I | 1 |
| Freynschlag, R; Gombotz, H; Hofer, A; Lechner, E; Leitner-Peneder, G; Mair, R; Rehak, P; Weinzettel, R | 1 |
| Cataldi, L; Toth-Heyn, P | 1 |
| Cho, S; Hara, T; Maekawa, T; Shibata, I; Sumikawa, K; Ureshino, H; Yoshitomi, O | 1 |
| Abrahamsson, P; Axelsson, B; Gupta, A; Haney, M; Johansson, G; Tydén, H; Wouters, P | 1 |
| Barrett, NA; Berry, WT; Hewson, RW; Langrish, CJ; McKenzie, CA | 1 |
| Andersen, GØ; Ata, SH; Dahl, CP; Levy, FO; Orstavik, O; Osnes, JB; Qvigstad, E; Riise, J; Skomedal, T | 1 |
| Calabrò, MG; Covello, RD; Greco, M; Greco, T; Landoni, G; Morelli, A; Pasin, L; Zangrillo, A | 1 |
| Burkhardt, BE; Rücker, G; Stiller, B | 1 |
| Bautista-Hernandez, V; Ferrer-Barba, A; Gonzalez-Rivera, I | 1 |
| Axelsson, B; Gupta, A; Häggmark, S; Haney, M; Johansson, G; Svenmarker, S; Tydén, H; Wouters, P | 1 |
| Ertl, G; Pauschinger, M; von Scheidt, W | 1 |
| Arya, VK; Dutta, V; Kumar, B; Mishra, A; Mishra, AK | 1 |
| Alaa, M; Leite, S; Leite-Moreira, AF; Lopes, L; Lourenço, AP; Oliveira-Pinto, J; Tavares-Silva, M | 1 |
| Bettex, D; Jacky, A; Krüger, B; Paal, S; Rudiger, A; Seifert, B; Spahn, DR; Wilhelm, MJ | 1 |
| Apostolopoulou, SC; Kakava, F; Rammos, S; Tsoutsinos, A; Vagenakis, GA | 1 |
| Hattori, K; Hattori, Y; Iguchi, K; Matsuda, N; Misawa, H; Nagata, T; Sakai, M; Sakamoto, T; Suzuki, T; Tomita, K; Watanabe, Y; Yamashita, S; Yokoo, H; Yoshimura, N | 1 |
| Fredholm, M; Houltz, E; Jörgensen, K; Ricksten, SE | 2 |
| Gandham, R; Kaur, P; Kundra, TS; Manjunatha, N; Prabhakar, V | 1 |
| Elhassan, A; Essandoh, M | 1 |
| Dempsey, E; Rabe, H | 1 |
| Castellheim, A; Keski-Nisula, J; Ricksten, SE; Romlin, BS; Suominen, PK; Synnergren, M; Thorlacius, EM; Vistnes, M; Wåhlander, H | 1 |
| Sharma, V; Tempe, DK | 1 |
| Biais, M; Carrie, C; Cottenceau, V; Gariel, F; Petit, L; Poutier, B; Sauvage, N | 1 |
| Akcan-Arikan, A; Alexander, PMA; Shekerdemian, LS | 1 |
| Castellheim, A; Keski-Nisula, J; Ojala, T; Ricksten, SE; Romlin, BS; Synnergren, M; Thorlacius, EM; Wåhlander, H; Ylänen, K | 1 |
| Eagle, SS; Staudt, GE | 1 |
| Chen, X; Lei, J; Liao, X; Qian, L; Zhang, S | 1 |
| Axelsson, B; Grafver, I; Jansson, K; Kiszakiewicz, L; Nilsson, KF; Oikonomakis, I; Seilitz, J | 1 |
| Castellheim, A; Keski-Nisula, J; Molin, M; Ojala, T; Ricksten, SE; Romlin, BS; Synnergren, M; Thorlacius, EM; Vistnes, M; Wåhlander, H | 1 |
| Banai, S; Frydman, S; Granot, Y; Havakuk, O; Hochstadt, A; Ketchker, L; Korotetski, L; Laufer-Perl, M; Milwidsky, A; Sadeh, B; Sapir, O; Topilsky, Y | 1 |
| Grossini, E; Levijoki, J; Papp, Z; Pollesello, P | 1 |
| Cheng, Z; Cui, X; Dong, X; Han, Y; Hong, Y; Huang, X; Li, Y; Mu, Y; Wang, Z; Zhang, L | 1 |
| Dosta-Herrera, JJ; Gutiérrez-Riveroll, KI; Mejía Picazo, HJ | 1 |
| Behera, SK; Chowdhury, SR; Das, M; Nag, P; Narayan, P | 1 |
| Burton, F; Dietrichs, ES; Ghasemi, M; Selli, AL; Smith, G; Watters, T | 1 |
15 review(s) available for simendan and milrinone
| Article | Year |
|---|---|
New therapeutic choices in the management of acute congestive heart failure.
Topics: Acute Disease; Heart Failure; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Quinolones; Simendan; Treatment Outcome; Vasodilator Agents | 2001 |
Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization.
Topics: Aged; Diuretics; Dobutamine; Enalaprilat; Female; Heart Failure; Hemodynamics; Hospitalization; Humans; Hydrazones; Injections, Intravenous; Male; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroprusside; Pulmonary Wedge Pressure; Pyridazines; Renal Agents; Simendan; Vasodilator Agents | 2003 |
New positive inotropic agents in the treatment of left ventricular dysfunction.
Topics: Cardiotonic Agents; Diastole; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Ischemia; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines; Simendan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2004 |
Optimizing outcomes in the patient with acute decompensated heart failure.
Topics: Biomarkers; Cardiotonic Agents; Diuretics; Heart Failure; Hemodynamics; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroglycerin; Pyridazines; Pyridines; Risk Assessment; Simendan; Tetrazoles; Therapeutics; Troponin; Vasodilator Agents; Ventricular Function, Left; Ventricular Pressure | 2006 |
Classical inotropes and new cardiac enhancers.
Topics: Algorithms; Cardiotonic Agents; Dobutamine; Dopamine; Heart Failure; Humans; Hydrazones; Milrinone; Practice Guidelines as Topic; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome | 2007 |
[Combination therapy with PDE III inhibitor for heart failure].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Chronic Disease; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 3; Dobutamine; Drug Therapy, Combination; Heart Failure; Humans; Hydrazones; Milrinone; Phosphodiesterase Inhibitors; Pyridazines; Simendan | 2007 |
Newer inotropes in pediatric heart failure.
Topics: Cardiotonic Agents; Child; Clinical Trials as Topic; Drug Administration Schedule; Etiocholanolone; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Contraction; Pyridazines; Simendan; Treatment Outcome | 2011 |
Neonatal blood pressure support: the use of inotropes, lusitropes, and other vasopressor agents.
Topics: Cardiotonic Agents; Cardiovascular System; Dobutamine; Dopamine; Epinephrine; Hemodynamics; Humans; Hydrazones; Infant, Newborn; Infant, Premature; Intensive Care Units, Neonatal; Milrinone; Pyridazines; Shock; Simendan; Vasoconstrictor Agents; Vasopressins | 2012 |
Vasoactive compounds in the neonatal period.
Topics: Adrenal Cortex Hormones; Cardiovascular System; Catecholamines; Humans; Hydrazones; Hypotension; Infant, Newborn; Milrinone; Pyridazines; Simendan; Vasodilator Agents; Vasopressins | 2012 |
A Bayesian network meta-analysis on the effect of inodilatory agents on mortality.
Topics: Bayes Theorem; Cardiac Surgical Procedures; Critical Illness; Dobutamine; Enoximone; Humans; Hydrazones; Milrinone; Pyridazines; Simendan; Vasodilator Agents | 2015 |
Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease.
Topics: Cardiac Output, Low; Cardiotonic Agents; Dobutamine; Heart Defects, Congenital; Humans; Hydrazones; Infant; Infant, Newborn; Milrinone; Postoperative Complications; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Syndrome; Time Factors | 2015 |
Inodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery.
Topics: Animals; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Child; Humans; Hydrazones; Milrinone; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Vasodilator Agents | 2016 |
Long-term intravenous inotropes in low-output terminal heart failure?
Topics: Administration, Intravenous; Cardiac Output; Cardiac Output, Low; Cardiotonic Agents; Chi-Square Distribution; Dobutamine; Drug Administration Schedule; Heart Failure; Heart Transplantation; Humans; Hydrazones; Milrinone; Odds Ratio; Practice Guidelines as Topic; Pyridazines; Risk Factors; Simendan; Time Factors; Treatment Outcome; Waiting Lists | 2016 |
The Use of Cardiotonic Drugs in Neonates.
Topics: Adrenal Cortex Hormones; Asphyxia Neonatorum; Cardiotonic Agents; Dobutamine; Dopamine; Heart Defects, Congenital; Humans; Hypotension; Infant, Newborn; Intensive Care Units, Neonatal; Milrinone; Neonatal Sepsis; Norepinephrine; Persistent Fetal Circulation Syndrome; Shock; Simendan; Vasoconstrictor Agents; Vasopressins | 2019 |
Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock.
Topics: Aged; Disease Progression; Dobutamine; Dopamine; Epinephrine; Female; Hemodynamics; Humans; Male; Middle Aged; Milrinone; Natriuretic Peptide, Brain; Network Meta-Analysis; Norepinephrine; Patient Safety; Recombinant Proteins; Shock, Cardiogenic; Simendan; Treatment Outcome | 2020 |
16 trial(s) available for simendan and milrinone
| Article | Year |
|---|---|
Levosimendan in cardiac surgery.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Artery Disease; Epinephrine; Female; Follow-Up Studies; Hemodynamics; Humans; Hydrazones; Male; Milrinone; Norepinephrine; Postoperative Care; Preoperative Care; Pyridazines; Risk Factors; Simendan; Time Factors; Vasoconstrictor Agents; Vasodilator Agents; Vasopressins; Ventricular Dysfunction, Left | 2005 |
Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery.
Topics: Adult; Aged; Blood Pressure; Cardiac Output, Low; Cardiopulmonary Bypass; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Elective Surgical Procedures; Female; Humans; Hydrazones; Male; Middle Aged; Milrinone; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Stroke Volume; Vascular Resistance | 2006 |
The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
Topics: Adrenergic beta-Agonists; Aged; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Dobutamine; Drug Administration Schedule; Drug Therapy, Combination; Elective Surgical Procedures; Female; Heart Diseases; Humans; Hydrazones; Intubation, Intratracheal; Length of Stay; Male; Middle Aged; Milrinone; Phosphodiesterase Inhibitors; Prospective Studies; Pyridazines; Simendan; Single-Blind Method; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2007 |
A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction.
Topics: Aged; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Female; Humans; Hydrazones; Male; Middle Aged; Milrinone; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Troponin I | 2008 |
Levosimendan in congenital cardiac surgery: a randomized, double-blind clinical trial.
Topics: Blood Pressure; Cardiac Surgical Procedures; Child, Preschool; Double-Blind Method; Heart Defects, Congenital; Heart Rate; Humans; Hydrazones; Infant; Infant, Newborn; Infusions, Intravenous; Milrinone; Prospective Studies; Pyridazines; Simendan | 2011 |
Levosimendan versus milrinone in neonates and infants after corrective open-heart surgery: a pilot study.
Topics: Analysis of Variance; Body Surface Area; Cardiac Output; Cardiac Output, Low; Cardiopulmonary Bypass; Cardiotonic Agents; Double-Blind Method; Female; Heart Defects, Congenital; Humans; Hydrazones; Infant; Infant, Newborn; Intention to Treat Analysis; Male; Milrinone; Pilot Projects; Premedication; Pyridazines; Simendan; Statistics, Nonparametric | 2012 |
Comparative Effect of Levosimendan and Milrinone in Cardiac Surgery Patients With Pulmonary Hypertension and Left Ventricular Dysfunction.
Topics: Adult; Aortic Valve; Arterial Pressure; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Humans; Hydrazones; Hypertension, Pulmonary; Male; Middle Aged; Milrinone; Mitral Valve; Norepinephrine; Postoperative Care; Prospective Studies; Pulmonary Artery; Pyridazines; Simendan; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Left | 2016 |
Comparison of Levosimendan and Milrinone for ECLS Weaning in Patients After Cardiac Surgery-A Retrospective Before-and-After Study.
Topics: Aged; Cardiac Surgical Procedures; Cardiotonic Agents; Extracorporeal Membrane Oxygenation; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Male; Middle Aged; Milrinone; Postoperative Care; Retrospective Studies; Shock, Cardiogenic; Simendan; Switzerland | 2018 |
Inotropic and lusitropic effects of levosimendan and milrinone assessed by strain echocardiography-A randomised trial.
Topics: Aged; Aortic Valve; Aortic Valve Stenosis; Cardiac Output; Cardiotonic Agents; Catheterization, Peripheral; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography, Transesophageal; Female; Heart; Heart Rate; Heart Valve Prosthesis Implantation; Humans; Male; Middle Aged; Milrinone; Myocardial Contraction; Pulmonary Wedge Pressure; Simendan; Stroke Volume | 2018 |
The Effect of Inhaled Milrinone Versus Inhaled Levosimendan in Pulmonary Hypertension Patients Undergoing Mitral Valve Surgery - A Pilot Randomized Double-Blind Study.
Topics: Administration, Inhalation; Adult; Blood Pressure; Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Valve Diseases; Humans; Hypertension, Pulmonary; Male; Milrinone; Mitral Valve; Pilot Projects; Prospective Studies; Pulmonary Wedge Pressure; Simendan; Treatment Outcome; Vascular Resistance | 2018 |
The Effect of Levosimendan Versus Milrinone on the Occurrence Rate of Acute Kidney Injury Following Congenital Heart Surgery in Infants: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Creatinine; Double-Blind Method; Female; Finland; Heart Defects, Congenital; Heart Septal Defects; Heart Septal Defects, Ventricular; Humans; Infant; Male; Milrinone; Prospective Studies; Simendan; Sweden; Tetralogy of Fallot | 2019 |
Levosimendan or milrinone for right ventricular inotropic treatment?-A secondary analysis of a randomized trial.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Cardiotonic Agents; Female; Heart Valve Prosthesis Implantation; Heart Ventricles; Humans; Male; Middle Aged; Milrinone; Prospective Studies; Simendan; Stroke Volume | 2020 |
Levosimendan Versus Milrinone for Inotropic Support in Pediatric Cardiac Surgery: Results From a Randomized Trial.
Topics: Cardiac Surgical Procedures; Cardiotonic Agents; Child; Humans; Hydrazones; Infant; Milrinone; Prospective Studies; Pyridazines; Simendan | 2020 |
Levosimendan Versus Milrinone and Release of Myocardial Biomarkers After Pediatric Cardiac Surgery: Post Hoc Analysis of Clinical Trial Data.
Topics: Biomarkers; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Humans; Infant; Milrinone; Simendan | 2021 |
[Levosimendan for preventing low output syndrome in pediatric patients with correction of tetralogy of Fallot].
Topics: Cardiac Output, Low; Cardiotonic Agents; Child; Humans; Hydrazones; Longitudinal Studies; Milrinone; Prospective Studies; Pyridazines; Simendan; Syndrome; Tetralogy of Fallot | 2022 |
Levosimendan or Milrinone for Ventricular Septal Defect Repair With Pulmonary Arterial Hypertension.
Topics: Cardiotonic Agents; Child; Heart Septal Defects, Ventricular; Heart Ventricles; Humans; Hydrazones; Milrinone; Prospective Studies; Pulmonary Arterial Hypertension; Pyridazines; Simendan | 2023 |
45 other study(ies) available for simendan and milrinone
| Article | Year |
|---|---|
A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts.
Topics: Amrinone; Animals; Cardiotonic Agents; Coronary Circulation; Electric Stimulation; Heart; Heart Rate; Hydrazones; In Vitro Techniques; Male; Milrinone; Myocardial Ischemia; Myocardium; NAD; Phosphodiesterase Inhibitors; Pyridazines; Pyridones; Rabbits; Simendan; Vasodilation; Ventricular Pressure | 1994 |
Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs.
Topics: Anesthesia; Animals; Cardiac Output; Dogs; Female; Hemodynamics; Hydrazones; Male; Milrinone; Phosphodiesterase Inhibitors; Pyridazines; Pyridones; Regional Blood Flow; Simendan | 1996 |
The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan.
Topics: Alkaloids; Animals; Calcium; Carbazoles; Cardiotonic Agents; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Guinea Pigs; Hydrazones; In Vitro Techniques; Indoles; Milrinone; Myocardial Contraction; Myocardium; Papillary Muscles; Perfusion; Phosphodiesterase Inhibitors; Protein Serine-Threonine Kinases; Pyridazines; Pyridones; Pyrroles; Simendan; Stimulation, Chemical | 1997 |
Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.
Topics: Calcium; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Milrinone; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Pyridazines; Simendan | 1998 |
Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Calcium; Cardiotonic Agents; Coronary Vessels; Cyclic Nucleotide Phosphodiesterases, Type 3; Hydrazones; Hydrogen-Ion Concentration; In Vitro Techniques; Milrinone; Muscle Relaxation; Muscle, Smooth, Vascular; Myocardial Contraction; Pyridazines; Simendan; Swine; Vasodilator Agents | 1999 |
Improved survival with simendan after experimental myocardial infarction in rats.
Topics: Animals; Antihypertensive Agents; Cardiotonic Agents; Enalapril; Hydrazones; Male; Milrinone; Myocardial Infarction; Pyridazines; Rats; Rats, Wistar; Simendan | 2001 |
Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart.
Topics: Animals; Dose-Response Relationship, Drug; Guinea Pigs; Heart; Hydrazones; In Vitro Techniques; Milrinone; Myocardial Contraction; Oxygen Consumption; Pyridazines; Simendan | 2004 |
Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs.
Topics: Adrenergic beta-Agonists; Animals; Cardiotonic Agents; Dobutamine; Dogs; Female; Gastric Mucosa; Hemodynamics; Hydrazones; Male; Microcirculation; Milrinone; Oxygen; Pyridazines; Simendan; Treatment Outcome; Vasodilator Agents | 2005 |
Levosimendan and gut mucosal blood flow--not all inotropes are created equal.
Topics: Animals; Cardiotonic Agents; Dobutamine; Dogs; Gastric Mucosa; Hemoglobinometry; Hydrazones; Microcirculation; Milrinone; Oxygen Consumption; Pyridazines; Simendan; Vasodilator Agents | 2005 |
Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Coronary Vessels; Dogs; Electrophysiology; Female; Heart Ventricles; Hemodynamics; Hydrazones; Male; Milrinone; Myocardial Reperfusion Injury; Pyridazines; Simendan; Ventricular Function | 2006 |
Testing new drugs for heart failure in children.
Topics: Adolescent; Cardiac Output, Low; Cardiotonic Agents; Catecholamines; Child; Child, Preschool; Humans; Hydrazones; Infant; Milrinone; Pyridazines; Simendan | 2006 |
Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass.
Topics: Age Factors; Animals; Cardiac Output; Cardiac Output, Low; Cardiopulmonary Bypass; Cardiotonic Agents; Diastole; Disease Models, Animal; Drug Evaluation, Preclinical; Heart Rate; Humans; Hydrazones; Infant; Milrinone; Oxygen Consumption; Pulmonary Gas Exchange; Pyridazines; Risk Factors; Simendan; Swine; Time Factors; Vascular Resistance; Ventricular Function, Left | 2007 |
Levosimendan in cardiac surgery: a unique drug for the treatment of perioperative left ventricular dysfunction or just another inodilator searching for a clinical application?
Topics: Adrenergic beta-Agonists; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Humans; Hydrazones; Milrinone; Myocardial Contraction; Perioperative Care; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents; Ventricular Dysfunction, Left | 2007 |
Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
Topics: Animals; Cardiotonic Agents; Diastole; Disease Models, Animal; Dobutamine; Heart Failure; Hydrazones; Lipopolysaccharides; Milrinone; Pyridazines; Rabbits; Sepsis; Simendan; Systole; Ventricular Function, Left | 2007 |
Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.
Topics: Acetamides; Animals; Blood Pressure; Calcium; Cardiac Output; Cardiotonic Agents; Cardiovascular System; Dobutamine; Dogs; Dose-Response Relationship, Drug; Heart Rate; Hydrazones; Male; Milrinone; Myocardial Contraction; Oxygen Consumption; Potassium; Potassium Channels; Pulmonary Circulation; Pyridazines; Simendan; Time Factors; Vascular Resistance; Vasodilator Agents; Ventricular Function, Left | 2008 |
Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and m
Topics: Animals; Blood Pressure; Cardiac Output; Cardiotonic Agents; Cardiovascular Physiological Phenomena; Dobutamine; Drug Combinations; Heart Rate; Hemodynamics; Hydrazones; Male; Milrinone; Myocardial Contraction; Pyridazines; Rats; Rats, Sprague-Dawley; Simendan; Vascular Resistance | 2008 |
Anti-ischemic effects of inotropic agents in experimental right ventricular infarction.
Topics: Animals; Blood Gas Analysis; Cardiotonic Agents; Dobutamine; Female; Heart Ventricles; Hemodynamics; Hydrazones; Inflammation Mediators; Milrinone; Myocardial Infarction; Myocardial Ischemia; Myocarditis; Myocardium; Myoglobin; Neutrophil Infiltration; Pyridazines; Simendan; Swine; Troponin T | 2009 |
Influence of temperature on the positive inotropic effect of levosimendan, dobutamine and milrinone.
Topics: Animals; Calcium; Cardiotonic Agents; Dobutamine; Dose-Response Relationship, Drug; Female; Guinea Pigs; Hydrazones; Hypothermia; In Vitro Techniques; Milrinone; Myocardial Contraction; Pyridazines; Random Allocation; Simendan; Temperature | 2009 |
Rotating inotrope therapy in a pediatric population with decompensated heart failure.
Topics: Adolescent; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Male; Milrinone; Pyridazines; Retrospective Studies; Simendan; Treatment Outcome | 2011 |
Age-dependent effects of milrinone and levosimendan on ventricular function and haemodynamics in newborn and mature pigs.
Topics: Age Factors; Animals; Animals, Newborn; Cardiotonic Agents; Hemodynamics; Hydrazones; Milrinone; Pyridazines; Simendan; Swine; Vasodilator Agents; Ventricular Function | 2011 |
Prevention for pediatric low cardiac output syndrome: results from the European survey EuLoCOS-Paed.
Topics: Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Child, Preschool; Dobutamine; Dopamine; Drug Therapy, Combination; Epinephrine; Europe; Health Care Surveys; Hospitals; Humans; Hydrazones; Infant; Milrinone; Pediatrics; Practice Patterns, Physicians'; Pyridazines; Simendan; Surveys and Questionnaires | 2011 |
How mechanical circulatory support helps not to need it--new strategies in pediatric heart failure.
Topics: Adolescent; Cardiomyopathies; Cardiotonic Agents; Catecholamines; Child, Preschool; Extracorporeal Membrane Oxygenation; Female; Heart Failure; Humans; Hydrazones; Infant; Male; Milrinone; Myocarditis; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2011 |
[Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
Topics: Acute Disease; Adolescent; Cardiotonic Agents; Child, Preschool; Dobutamine; Heart Failure; Humans; Hydrazones; Male; Milrinone; Pyridazines; Simendan | 2011 |
Mechanism of cardioprotective effect of adenocine and non-glycoside cardiotonic drugs during experimental chronic cardiac insufficiency.
Topics: Acetyldigoxins; Adenosine; Adenosine Triphosphate; Animals; Apoptosis; Cardiotonic Agents; Constriction, Pathologic; Female; Heart; Heart Failure; Heart Ventricles; Hydrazones; Male; Milrinone; Myocardium; Myocytes, Cardiac; NAD; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Pyridazines; Rabbits; Reperfusion; Simendan; Ventricular Function | 2011 |
Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts.
Topics: Animals; Blood Glucose; Disease Models, Animal; Hemodynamics; Hydrazones; Hyperglycemia; Male; Milrinone; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Pyridazines; Rats; Rats, Wistar; Simendan; Time Factors | 2012 |
Pharmacologic interventions to improve splanchnic oxygenation during ventilation with positive end-expiratory pressure.
Topics: Anesthesia, Epidural; Dobutamine; Dopamine; Humans; Hydrazones; Milrinone; Oxygen; Oxygen Consumption; Oxyhemoglobins; Positive-Pressure Respiration; Pulmonary Ventilation; Pyridazines; Receptors, Catecholamine; Simendan; Splanchnic Circulation; Vital Capacity | 2012 |
Milrinone is preferred to levosimendan for mesenteric perfusion in hypoxia-reoxygenated newborn piglets treated with dopamine.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Dopamine; Drug Therapy, Combination; Hemodynamics; Hydrazones; Hypoxia; Mesenteric Arteries; Milrinone; Models, Animal; Myocardial Reperfusion; Myocardial Reperfusion Injury; Oxidative Stress; Pyridazines; Simendan; Swine; Vasodilator Agents | 2012 |
Milrinone and levosimendan administered after reperfusion improve myocardial stunning in swine.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Drug Administration Schedule; Female; Hemodynamics; Hydrazones; Male; Milrinone; Myocardial Contraction; Myocardial Reperfusion Injury; Myocardial Stunning; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridazines; Simendan; Swine; Time Factors | 2013 |
Milrinone and levosimendan during porcine myocardial ischemia -- no effects on calcium overload and metabolism.
Topics: Animals; Calcium; Calcium Radioisotopes; Cardiotonic Agents; Drug Evaluation, Preclinical; Energy Metabolism; Glucose; Glycolysis; Heart Ventricles; Hemodynamics; Hydrazones; Infusions, Intravenous; Ion Transport; Microdialysis; Milrinone; Myocardial Ischemia; Myocytes, Cardiac; Oxygen Consumption; Premedication; Pyridazines; Random Allocation; Simendan; Sus scrofa; Swine | 2013 |
Levosimendan: a retrospective single-center case series.
Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Hemodynamics; Hospital Mortality; Humans; Hydrazones; Intensive Care Units; Male; Milrinone; Norepinephrine; Pyridazines; Retrospective Studies; Simendan; Sympathomimetics; Treatment Outcome | 2013 |
Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydrazones; In Vitro Techniques; Isoproterenol; Male; Milrinone; Myocardial Contraction; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Pyridazines; Quinolines; Quinolones; Rats, Wistar; Rolipram; Simendan; Thiadiazines | 2014 |
Effects of Combined Milrinone and Levosimendan Treatment on Systolic and Diastolic Function During Postischemic Myocardial Dysfunction in a Porcine Model.
Topics: Animals; Cardiotonic Agents; Diastole; Disease Models, Animal; Drug Therapy, Combination; Hydrazones; Milrinone; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardial Stunning; Pyridazines; Recovery of Function; Simendan; Sus scrofa; Systole; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure | 2016 |
Dose-Response Head-to-Head Comparison of Inodilators Dobutamine, Milrinone, and Levosimendan in Chronic Experimental Pulmonary Hypertension.
Topics: Animals; Calcium; Chronic Disease; Dobutamine; Dose-Response Relationship, Drug; Hemodynamics; Hydrazones; Hypertension, Pulmonary; Male; Milrinone; Pyridazines; Rats; Rats, Wistar; Simendan | 2017 |
Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation.
Topics: Adolescent; Adult; Cardiotonic Agents; Child; Child, Preschool; Dobutamine; Female; Follow-Up Studies; Heart Failure; Heart Transplantation; Humans; Infant; Infusions, Intravenous; Male; Milrinone; Retrospective Studies; Simendan; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Cardioprotective and functional effects of levosimendan and milrinone in mice with cecal ligation and puncture-induced sepsis.
Topics: Animals; Calcium; Cardiotonic Agents; Cecum; Cytokines; Ligation; Male; Mice, Inbred BALB C; Milrinone; Myocardium; Myocytes, Cardiac; Sepsis; Simendan; Ventricular Function, Left; Wounds, Penetrating | 2018 |
Inhaled Levosimendan for Pulmonary Hypertension Treatment During Cardiac Surgery: A Novel Application to Avoid Systemic Hypotension.
Topics: Double-Blind Method; Humans; Hypertension, Pulmonary; Hypotension; Milrinone; Mitral Valve; Pilot Projects; Simendan | 2019 |
The Effect of Inhaled Milrinone Versus Inhaled Levosimendan in Pulmonary Hypertension Patients Undergoing Mitral Valve Surgery.
Topics: Double-Blind Method; Humans; Hypertension, Pulmonary; Milrinone; Mitral Valve; Pilot Projects; Simendan | 2019 |
May levosimendan be safe and effective in refractory vasospasm despite adequate treatment with repeated angiography and milrinone infusion after subarachnoid haemorrhage?
Topics: Aneurysm, Ruptured; Cardiotonic Agents; Cerebral Angiography; Cerebrospinal Fluid Leak; Computed Tomography Angiography; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Embolization, Therapeutic; Humans; Infusions, Intravenous; Intracranial Aneurysm; Intracranial Pressure; Magnesium Sulfate; Male; Middle Aged; Milrinone; Nimodipine; Simendan; Subarachnoid Hemorrhage; Vasospasm, Intracranial; Ventricular Dysfunction, Left | 2019 |
Another Outcome Lost to the Benefits of Levosimendan?
Topics: Acute Kidney Injury; Cardiotonic Agents; Heart Defects, Congenital; Humans; Milrinone; Simendan | 2019 |
A Tale of 2 Inodilators: Much Ado About Nothing?
Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Child; Heart; Humans; Milrinone; Simendan | 2020 |
A Randomized Porcine Study in Low Cardiac Output of Vasoactive and Inotropic Drug Effects on the Gastrointestinal Tract.
Topics: Animals; Cardiac Output, Low; Disease Models, Animal; Female; Gastrointestinal Tract; Male; Milrinone; Norepinephrine; Random Allocation; Simendan; Splanchnic Circulation; Swine; Vasodilator Agents; Vasopressins | 2021 |
Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients.
Topics: Aged; Aged, 80 and over; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Milrinone; Pyridazines; Quality of Life; Simendan; Stroke Volume; Ventricular Function, Left | 2022 |
The Adenylate Cyclase Activator Forskolin Potentiates the Positive Inotropic Effect of the Phosphodiesterase Inhibitor Milrinone But Not of the Calcium Sensitizer Levosimendan nor of Its Hemodynamically Active Metabolites: An Apparent Conundrum.
Topics: Adenylyl Cyclases; Animals; Calcium; Cardiotonic Agents; Colforsin; Guinea Pigs; Milrinone; Myocardial Contraction; Phosphodiesterase Inhibitors; Simendan | 2022 |
Comparative Effectiveness and Safety of Milrinone and Levosimendan as Initial Inotrope Therapy in Patients With Acute Heart Failure With Renal Dysfunction.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Kidney Diseases; Milrinone; Pyridazines; Retrospective Studies; Simendan | 2022 |
Proarrhythmic changes in human cardiomyocytes during hypothermia by milrinone and isoprenaline, but not levosimendan: an experimental in vitro study.
Topics: Cardiotonic Agents; Heart Diseases; Humans; Hydrazones; Hypothermia; Isoproterenol; Milrinone; Myocytes, Cardiac; Pyridazines; Simendan | 2023 |